TXG Market Analysis

Wall Street coverage

third-party context

Wall Street coverage

$41.54median target· current $47.27 (-12.1%)16 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

News & Sentiment

50 articles · sorted by date
Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Fundamentals

Updated daily after market close
P/E ratioForward 769.23
EPS (TTM)$-0.170.0% YoY
Profit margin-3.5%HEALTHCARE
Market cap$6.00BMid cap

Valuation

Forward P/E
769.23
PEG ratio
P/B
7.37
P/S (TTM)
9.39
EV/EBITDA
147.86

Profitability & growth

ROE (TTM)
-3.0%
Operating margin
-11.3%
Revenue growth YoY
-2.6%
Dividend yield
Beta
2.04
Last earnings
May 7, 2026 · Estimate $-0.06 · Reported $0.07
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

About 10X Genomics Inc

Company profile

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Fiscal year end
December
Latest quarter
Mar 31, 2026
Market cap$6.00B
Shares outstanding$116.9M
52W high$50.34
52W low$11.16

We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer